ReviewAllergy, asthma & immunology research2016
Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity.
Review in Allergy, asthma & immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 122 citations in OpenAlex.
- Increased serum antibody responses to Aspergillus fumigatus and house dust mite antigens in dogs with idiopathic eosinophilic bronchopneumopathy.Journal of veterinary internal medicine · 2026Article
- [Allergic bronchopulmonary aspergillosis-essential knowledge for radiology].Radiologie (Heidelberg, Germany) · 2026Review
- Pathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus for immunodiagnostic/immunotherapeutic applications against allergic aspergillosis.Annals of clinical microbiology and antimicrobials · 2026Article
- Serological and biochemical characterization of Aspergillus fumigatus Asp f 10 as a potential diagnostic marker in ABPA and related respiratory diseases.Frontiers in allergy · 2026Article
- Eosinophil-Derived Neurotoxin: A Potential Biomarker for Allergic Bronchopulmonary Aspergillosis.Journal of asthma and allergy · 2026Article
- A Case Report of Refractory Allergic Bronchopulmonary Aspergillosis: The Art of Selection, Discontinuation and Switching Biologics.Journal of inflammation research · 2026Article
- Review
- Clinical significance of very high IgE levels (≥1000 IU/mL): Population-based study of 118,211 adults.The journal of allergy and clinical immunology. Global · 2025Article
- Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Article
- A Multiplex PCR Melting-Curve-Analysis-Based Detection Method for the Discrimination of FiveJournal of fungi (Basel, Switzerland) · 2023Article
- Review
- T-cell epitope-based vaccine prediction against Aspergillus fumigatus: a harmful causative agent of aspergillosis.Journal, genetic engineering & biotechnology · 2022Article
- Comparison ofFrontiers in microbiology · 2022Article
- Clinical and immunological characteristics ofFrontiers in immunology · 2022Article
- Allergic Bronchopulmonary Aspergillosis with an Atypical Mass-Like Presentation.Case reports in pulmonology · 2022Article
- Review
- "Allergic bronchopulmonary aspergillosis misdiagnosed as smear negative pulmonary tuberculosis; a retrospective study from Pakistan".Annals of medicine and surgery (2012) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In susceptible individuals, inhalation of Aspergillus spores can affect the respiratory tract in many ways. These spores get trapped in the viscid sputum of asthmatic subjects which triggers a cascade of inflammatory reactions that can result in Aspergillus-induced asthma, allergic bronchopulmonary aspergillosis (ABPA), and allergic Aspergillus sinusitis (AAS). An immunologically mediated disease, ABPA, occurs predominantly in patients with asthma and cystic fibrosis (CF). A set of criteria, which is still evolving, is required for diagnosis. Imaging plays a compelling role in the diagnosis and monitoring of the disease. Demonstration of central bronchiectasis with normal tapering bronchi is still considered pathognomonic in patients without CF. Elevated serum IgE levels and Aspergillus-specific IgE and/or IgG are also vital for the diagnosis. Mucoid impaction occurring in the paranasal sinuses results in AAS, which also requires a set of diagnostic criteria. Demonstration of fungal elements in sinus material is the hallmark of AAS. In spite of similar histopathologic features, co-existence of ABPA and AAS is still uncommon. Oral corticosteroids continue to be the mainstay of management of allergic aspergillosis. Antifungal agents play an adjunctive role in ABPA as they help reduce the fungal load. Saprophytic colonization in cavitary ABPA may lead to aspergilloma formation, which could increase the severity of the disease. The presence of ABPA, AAS, and aspergilloma in the same patient has also been documented. All patients with Aspergillus-sensitized asthma must be screened for ABPA, and AAS should always be looked for.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.